Answers are grounded in this paper and cite their sources.
Sustained inflammation in the colon fosters a pro-tumorigenic environment, leading to the initiation and progression of CA-CRC. Prevention strategies must focus on controlling chronic inflammation, optimizing IBD management, and implementing regular screenings. Emerging therapies targeting key inflammatory pathways and immune responses, along with microbiome modulation, hold promise for reducing CA-CRC risk. Understanding these molecular mechanisms provides a path toward personalized treatment and better outcomes for patients with IBD at risk of colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Khaze et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: